Luminary Therapeutics and Case Western Reserve University Enter Formal Collaboration for Development of BAFF CAR
Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome
MINNEAPOLIS, MN, USA, July 7, 2020– Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs. [Read more…]
AASCP to Host 1st Virtual Board Certification Ceremony for Stem Cell Physicians
The American Academy of Stem Cell Physicians (AAOSCP) will create history on August 2, 2020, by hosting the first virtual Board Certification for Stem Cell Physicians.
On August 2-4, 2019, the American Academy of Stem Cell Physicians hosted a Scientific Congress at the Hyatt Regency in Miami, Florida. The highly anticipated event featured three days of educational and events with leading physicians and pioneers from across the fields of stem cell, live cell and regenerative medicine.
During this event, the AASCP Scientific Congress offered the first Board Certifications to eligible stem cell physicians. A challenging three-hour written examination for Board Certification was conducted, creating a pathway for Diplomat and Fellowship Certification in Regenerative Medicine (RM).
This year, the AASCP’s Congress will be delivered over August 1-2, 2020, and will include the first Virtual Board Certification for Stem Cell Physicians. [Read more…]
Aspire Health Science LLC, Announces Release of ACP-01 Midpoint Analysis to Hemostemix Inc.
ORLANDO, Fla., July 6, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), is an FDA registered cGMP manufacturing facility specializing in the research, development, and manufacturing of cell-based therapies. [Read more…]
Citius to Pursue IND for Use of Its Induced MSCs in COVID-19 Induced ARDS
-
Citius receives FDA Response on Pre-IND application for its induced mesenchymal stem cells (iMSCs) to treat ARDS induced by COVID-19
-
FDA provides specific guidelines to study iPSC-derived MSCs, preparing Citius to submit an IND application for its iMSC therapy
-
The Citius iMSC is an allogeneic MSC product manufactured by expanding material from a master cell bank
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 96
- Next Page »